Global Transcatheter Heart Valve Replacement (TAVI) Market is poised to register a CAGR of 12% during the forecast period 2022 to 2028.
The natural heart valves (aortic pulmonary, mitral, mitral, and tricuspid), act as one-way valves that direct blood flow to the lungs. The standard treatment for structural heart valve disorders involves open-heart surgery with a cardiopulmonary bypass. Percutaneous and catheter-based transcatheter valve procedures utilize catheter technology to access the heart. This allows for the management of heart valve disorders and prevents the need for cardiopulmonary bypass and open-heart surgery. The procedure involves attaching a compression artificial heart valve or another device to a wire frame that is guided by a catheter. Once the wireframe is in place, it expands and allows the device to fully open. This procedure involves inserting a catheter into the leg, chest, or heart and guiding it to the right. TAVR is a crucial procedure as it corrects the sensitive function of your heart with respect to the valves. TAVR is a procedure that restores blood flow and can reduce symptoms such as fatigue, chest pain, shortness or breath, fainting, and other signs of aortic valve stenosis. TAVR is an option for those who are at high risk of complications after open-heart surgery to replace their aortic valve. Surgery with a prosthetic valve is the best option for severe and symptomatic aortic stenosis. Transcatheter aortic replacement (TAVR), is a minimally invasive option to surgery. The procedure of replacing a valve usually requires open-heart surgery and sternotomy. This involves the surgical opening of the chest. It also includes transcatheter or transaortic aortic vales to restore the valve’s circulation system capabilities. Surgery is the main treatment for valvular disease. Traditionally, catheter-based treatments have been limited in the treatment of stenotic lesions of aortic, mitral and pulmonary valves. Recent advances in technology have made percutaneous valvular interventions much more effective.
The Transcatheter Heart Valve Replacement (TAVI) report examines market segmentation forecasts by product, by surgical approach, by application, by end use, and by region. This report offers thorough information on the industry’s profit, a SWOT analysis of market trends, significant rivals, and a market geographical study.
Key Market Players:
4C Medical Technologies, Abbott, Boston Scientific, Edwards Lifesciences, HighLife Medical, JC Medical, LivaNova, Medtronic plc., and more.
(Note: Please visit the report page for a comprehensive list of significant players.)
The Transcatheter Heart Valve Replacement (TAVI) Market’s regional overview is divided into North America, Europe, Latin America, Asia-Pacific, the Middle East and Africa, and the Rest of the World.
Europe is the market leader in transcatheter aortic replacement (TAVR). This is due to the rising prevalence of aortic stenosis, and the excellent healthcare infrastructure. There is a significant amount of symptomatic aortic stenosis in the UK. This is due to an increase in high-risk patients with aortic disease. Transcatheter aortic valve implantation markets in Asia-Pacific are lucrative for players. This is due to the large population and a variety of lifestyle diseases.
Objectives of the Study:
- To provide a report that contains a detailed analysis of the Transcatheter Heart Valve Replacement (TAVI) Market by product, by surgical approach, by application, by end use, and by region.
- To give detailed statistics and data points on market-moving factors (drivers, opportunities, and industry-specific restraints)
- To evaluate and forecast micro-markets as well as the entire scope of the market.
- To forecast market trends, size, and overview in key regions including North America, Europe, Asia Pacific, the Middle East, and Africa, as well as the rest of the world.
- To stay on top of the competitive environment, including new product launches, mergers and acquisitions, and technological developments, and to assess them.